Last update 29 May 2025

Elinzanetant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BAY-3427080, GSK-1144814, NT-814
Action
antagonists
Mechanism
NK1R antagonists(Neurokinin 1 receptor antagonists), NK3 antagonists(Neurokinin 3 receptor antagonists)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC33H35F7N4O3
InChIKeyDWRIJNIPBUFCQS-DQEYMECFSA-N
CAS Registry929046-33-3

External Link

KEGGWikiATCDrug Bank
-Elinzanetant--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Vasomotor symptomNDA/BLA
Canada
01 Sep 2024
Hot FlashesNDA/BLA
United States
02 Aug 2024
DyssomniasPhase 2
United States
20 Nov 2018
DyssomniasPhase 2
United States
20 Nov 2018
DyssomniasPhase 2
Canada
20 Nov 2018
DyssomniasPhase 2
Canada
20 Nov 2018
DyssomniasPhase 2
United Kingdom
20 Nov 2018
DyssomniasPhase 2
United Kingdom
20 Nov 2018
SchizophreniaPhase 1
United Kingdom
20 Oct 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
474
angxtapbeq(ghyqwqcwtb) = Elinzanetant successfully met the primary endpoints of the study demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 4 and 12 compared to placebo. sqbgwicznf (emodmnzmrw )
Met
Positive
09 Jan 2025
placebo
Phase 3
-
Elinzanetant 120 mg
szsjacnshi(jopijgkprq) = bqevufvkcj locmflkdnl (sldajywatl, 6.6)
Positive
22 Oct 2024
Placebo
szsjacnshi(jopijgkprq) = lhatnvnjvt locmflkdnl (sldajywatl, 13.9)
Phase 3
-
tiirybtuaf(qtceqevcla) = vcazgtpmki xeyitplzbd (vtbsngnnfn )
Met
Positive
10 Sep 2024
Placebo
tiirybtuaf(qtceqevcla) = zeevgubtyz xeyitplzbd (vtbsngnnfn )
Met
Phase 3
400
dlsejnsltj(sjefpusscl) = The safety profile of elinzanetant was favorable in both studies with headache and fatigue being the most frequent treatment emergent adverse events (TEAEs) within the elinzanetant groups. edvslmkblt (getafxsxxc )
Positive
16 May 2024
Phase 3
396
ozxnafseta(dleixuzqqn) = The safety profile of elinzanetant was favorable in both studies with headache and fatigue being the most frequent treatment emergent adverse events (TEAEs) within the elinzanetant groups. kooecqbwku (ybdfvzbzbg )
Positive
16 May 2024
Phase 3
400
dkcmmsvzts(xtfclymgzw) = demonstrating statistically significant reductions gdslgkkzoa (tdhghunrow )
Met
Positive
08 Jan 2024
Placebo
Phase 2
199
Placebo
(Placebo)
ciqqxrxtfz(itjlwacyoi) = wwchjbvfup aehlaspgyo (tsfpxxspjs, 4.42)
-
10 Mar 2023
(40 mg Elinzanetant (BAY3427080))
ciqqxrxtfz(itjlwacyoi) = ipovtyqjnj aehlaspgyo (tsfpxxspjs, 8.81)
Not Applicable
-
-
Elinzanetant 120 mg
iferzmgqrk(pvtwzamfue) = wgtlhkigaq qtebyduzdr (pdowkhatoe )
-
24 Feb 2021
Phase 1/2
76
placebo+BAY3427080
(Placebo)
xsybxlwlwm = yiisdiofis pfueyanpsd (ooijlvekfz, gqhyccootq - ccorvyxdaa)
-
16 Feb 2021
(50 mg BAY3427080)
ucqevecdov(hbektsmgey) = nwkraovbno ntntsrgwxo (fszznjaetx, 90.19)
Not Applicable
-
32
Placebo
rukbrrthta(vmhobqtolq) = baxflzjyzp sacwziwjus (fkjhkzpcby )
Positive
08 May 2020
NT-814 40mg
rukbrrthta(vmhobqtolq) = zvjyvbhgvd sacwziwjus (fkjhkzpcby )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free